MODACIN

Modacin Adverse Events Reported to the FDA Over Time

How are Modacin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Modacin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Modacin is flagged as the suspect drug causing the adverse event.

Most Common Modacin Adverse Events Reported to the FDA

What are the most common Modacin adverse events reported to the FDA?

Hepatic Function Abnormal	44 (4.03%)
Alanine Aminotransferase Increased	31 (2.84%)
Pyrexia	31 (2.84%)
Aspartate Aminotransferase Increase...	29 (2.66%)
Gamma-glutamyltransferase Increased	22 (2.02%)
Blood Alkaline Phosphatase Increase...	19 (1.74%)
Erythema	18 (1.65%)
Liver Disorder	17 (1.56%)
Rash	16 (1.47%)
Toxic Epidermal Necrolysis	16 (1.47%)
Depressed Level Of Consciousness	14 (1.28%)
	Show More
Drug Eruption	14 (1.28%)
Renal Failure Acute	14 (1.28%)
Blood Pressure Decreased	13 (1.19%)
Platelet Count Decreased	13 (1.19%)
Wheezing	13 (1.19%)
Acute Generalised Exanthematous Pus...	12 (1.1%)
Convulsion	12 (1.1%)
Eosinophil Count Increased	12 (1.1%)
Generalised Erythema	12 (1.1%)
Shock	12 (1.1%)
Anaphylactic Shock	10 (.92%)
Sepsis	10 (.92%)
Ascites	9 (.82%)
Blood Bilirubin Increased	9 (.82%)
Blood Lactate Dehydrogenase Increas...	9 (.82%)
Dyspnoea	9 (.82%)
Cyanosis	8 (.73%)
Rash Erythematous	8 (.73%)
Stevens-johnson Syndrome	8 (.73%)
Blister	7 (.64%)
C-reactive Protein Increased	7 (.64%)
Diarrhoea	7 (.64%)
Hallucination	7 (.64%)
Hyperhidrosis	7 (.64%)
Nausea	7 (.64%)
Pneumonia	7 (.64%)
Renal Disorder	7 (.64%)
Renal Impairment	7 (.64%)
Urinary Incontinence	7 (.64%)
Delirium	6 (.55%)
Disseminated Intravascular Coagulat...	6 (.55%)
Drug Exposure During Pregnancy	6 (.55%)
Haemorrhage	6 (.55%)
Pallor	6 (.55%)
Parosmia	6 (.55%)
Blood Urea Increased	5 (.46%)
Body Temperature Increased	5 (.46%)
Cachexia	5 (.46%)
Cardiac Failure	5 (.46%)
Conjunctival Hyperaemia	5 (.46%)
Drug Level Increased	5 (.46%)
Dysgeusia	5 (.46%)
Dyskinesia	5 (.46%)
Excoriation	5 (.46%)
Generalised Oedema	5 (.46%)
Hypercapnia	5 (.46%)
Multi-organ Failure	5 (.46%)
Oedema	5 (.46%)
Pancytopenia	5 (.46%)
Respiratory Arrest	5 (.46%)
Staphylococcal Infection	5 (.46%)
Abdominal Pain Upper	4 (.37%)
Abnormal Behaviour	4 (.37%)
Cardiac Arrest	4 (.37%)
Constipation	4 (.37%)
Cough	4 (.37%)
Face Oedema	4 (.37%)
Haematemesis	4 (.37%)
Heart Rate Increased	4 (.37%)
Hypersensitivity	4 (.37%)
Ileus Paralytic	4 (.37%)
Infection	4 (.37%)
Intestinal Dilatation	4 (.37%)
Memory Impairment	4 (.37%)
Mouth Breathing	4 (.37%)
Oliguria	4 (.37%)
Painful Respiration	4 (.37%)
Prolonged Expiration	4 (.37%)
Pseudomembranous Colitis	4 (.37%)
Red Blood Cell Count Decreased	4 (.37%)
Skin Erosion	4 (.37%)
Speech Disorder	4 (.37%)
Stomatitis	4 (.37%)
Thrombocytopenia	4 (.37%)
Urine Output Decreased	4 (.37%)
Vomiting	4 (.37%)
White Blood Cell Count Decreased	4 (.37%)
White Blood Cell Count Increased	4 (.37%)
Abdominal Pain	3 (.27%)
Acute Respiratory Distress Syndrome	3 (.27%)
Altered State Of Consciousness	3 (.27%)
Blood Creatine Phosphokinase Increa...	3 (.27%)
Brain Oedema	3 (.27%)
C-reactive Protein Decreased	3 (.27%)
Clostridium Colitis	3 (.27%)
Cystitis Haemorrhagic	3 (.27%)
Dermatitis Exfoliative	3 (.27%)
Dysphagia	3 (.27%)
Electroencephalogram Abnormal	3 (.27%)
Encephalopathy	3 (.27%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Modacin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Modacin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Modacin

What are the most common Modacin adverse events reported to the FDA?

Epidermal And Dermal Conditions	128 (11.73%)
Hepatobiliary	95 (8.71%)
Hepatic And Hepatobiliary	65 (5.96%)
Hematology Investigations	56 (5.13%)
Respiratory	46 (4.22%)
Neurological	40 (3.67%)
Infections - Pathogen Unspecified	36 (3.3%)
Body Temperature Conditions	34 (3.12%)
Renal Disorders	34 (3.12%)
Enzyme	31 (2.84%)
Gastrointestinal Signs	21 (1.92%)
	Show More
Allergic Conditions	20 (1.83%)
Cardiac And Vascular Investigations	19 (1.74%)
Gastrointestinal Motility And Defec...	19 (1.74%)
Bronchial Disorders	16 (1.47%)
Decreased And Nonspecific Blood Pre...	15 (1.37%)
Protein And Chemistry Analyses	15 (1.37%)
Renal And Urinary Tract Investigati...	14 (1.28%)
Bacterial Infectious	13 (1.19%)
Seizures	12 (1.1%)
Skin Appendage Conditions	12 (1.1%)
White Blood Cell	12 (1.1%)
Peritoneal And Retroperitoneal Cond...	10 (.92%)
Anemias Nonhemolytic And Marrow Dep...	9 (.82%)
Disturbances In Thinking	9 (.82%)
Lower Respiratory Tract Disorders	9 (.82%)
Movement Disorders	9 (.82%)
Urinary Tract Signs	9 (.82%)
Cardiac Disorder Signs	8 (.73%)
Muscle	8 (.73%)
Ocular Infections, Irritations And ...	8 (.73%)
Oral Soft Tissue Conditions	8 (.73%)
Coagulopathies And Bleeding Diathes...	7 (.64%)
Encephalopathies	7 (.64%)
Heart Failures	7 (.64%)
Chemical Injury And Poisoning	6 (.55%)
Cranial Nerve Disorders	6 (.55%)
Deliria	6 (.55%)
Gastrointestinal Inflammatory Condi...	6 (.55%)
Skin And Subcutaneous Tissue	6 (.55%)
Vascular	6 (.55%)
Vascular Hemorrhagic	6 (.55%)
Appetite And General Nutritional	5 (.46%)
Gastrointestinal Hemorrhages	5 (.46%)
Hemolyses And Related Conditions	5 (.46%)
Injuries	5 (.46%)
Physical Examination Topics	5 (.46%)
Psychiatric And Behavioural Symptom...	5 (.46%)
Skin Vascular Abnormalities	5 (.46%)
Toxicology And Therapeutic Drug Mon...	5 (.46%)
Administration Site Reactions	4 (.37%)
Cardiac Arrhythmias	4 (.37%)
Central Nervous System Vascular	4 (.37%)
Electrolyte And Fluid Balance Condi...	4 (.37%)
Immune	4 (.37%)
Mental Impairment	4 (.37%)
Platelet	4 (.37%)
Procedural And Device Related Injur...	4 (.37%)
Therapeutic And Nontherapeutic Effe...	4 (.37%)
Bladder And Bladder Neck Disorders	3 (.27%)
Embolism And Thrombosis	3 (.27%)
Gastrointestinal	3 (.27%)
Increased Intracranial Pressure And...	3 (.27%)
Miscellaneous And Site Unspecified ...	3 (.27%)
Neonatal And Perinatal Conditions	3 (.27%)
Neurological, Special Senses And Ps...	3 (.27%)
Ocular Neuromuscular	3 (.27%)
Sleep Disorders	3 (.27%)
Viral Infectious	3 (.27%)
Demyelinating	2 (.18%)
Exocrine Pancreas Conditions	2 (.18%)
Eye	2 (.18%)
Hearing	2 (.18%)
Immunology And Allergy	2 (.18%)
Inner Ear And Viiith Cranial Nerve	2 (.18%)
Maternal Complications Of Labour An...	2 (.18%)
Metastases	2 (.18%)
Microbiology And Serology	2 (.18%)
Pleural	2 (.18%)
Tongue Conditions	2 (.18%)
Water, Electrolyte And Mineral	2 (.18%)
Angiedema And Urticaria	1 (.09%)
Arteriosclerosis, Stenosis, Vascula...	1 (.09%)
Cardiac Valve	1 (.09%)
Eating Disorders	1 (.09%)
Fatal Outcomes	1 (.09%)
Fungal Infectious	1 (.09%)
Gastrointestinal Therapeutic Proced...	1 (.09%)
Impulse Control	1 (.09%)
Male Reproductive Tract Infections ...	1 (.09%)
Medication Errors	1 (.09%)
Metabolic, Nutritional And Blood Ga...	1 (.09%)
Nephropathies	1 (.09%)
Parathyroid Gland	1 (.09%)
Red Blood Cell	1 (.09%)
Upper Respiratory Tract Disorders	1 (.09%)
Vascular Inflammations	1 (.09%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Modacin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Modacin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.